Welcome to our dedicated page for BIOTRICITY news (Ticker: BTCY), a resource for investors and traders seeking the latest updates and insights on BIOTRICITY stock.
Biotricity, Inc. (BTCY) is a medical technology company at the forefront of healthcare innovation. Specializing in biometric data monitoring solutions, Biotricity aims to improve healthcare by developing remote monitoring solutions for chronic disease prevention and management. Its premier product, Bioflux, is an ECG monitoring system used by physicians to diagnose and monitor cardiac patients remotely. Biotricity's Biolife solution extends medical-grade monitoring to the consumer market, empowering users to self-manage chronic conditions through lifestyle changes. With a focus on preventive healthcare, Biotricity's R&D efforts aim to put health management directly into the hands of individuals, easing the burden on the healthcare system.
Biotricity, Inc. (OTCQB:BTCY) reported strong financial results for Q4 and fiscal year 2021, with Q4 revenue reaching $1.2 million, reflecting an 8th consecutive quarter of triple-digit year-over-year growth. This quarter saw a 227% increase in revenue, surpassing the previous quarter's 162%. The annual revenue totaled $3.4 million, up 139% from fiscal 2020. Despite a net loss of $16.2 million, management anticipates further growth, targeting triple-digit revenue increases for fiscal 2022.
Biotricity, Inc. (OTCQB:BTCY) will release its financial results for the fourth quarter and full fiscal year 2021, ending March 31, 2021, on June 15, 2021, post-market close. A live conference call will occur at 1:30 p.m. PT (4:30 p.m. ET) on the same day to discuss these results. Interested parties can join via phone at +1 334-777-6978 or toll-free at 800-367-2403, using passcode 3169700. Additionally, a webcast will be available on the company's website for further access and replay.
Biotricity Inc. (BTCY) announced that CEO Waqaas Al-Siddiq will present at the LD Micro Invitational XI on June 8, 2021, at 11:30 a.m. EDT. The presentation will focus on the company's vision for diagnostic solutions and an update on growth following record fiscal 2021 results. Attendees can register for the presentation here. Following the event, management will hold one-on-one virtual meetings on June 8 and 9. The LD Micro Invitational will feature approximately 180 companies and influential keynote speakers.
Biotricity, Inc. (OTCQB:BTCY) has initiated its strategy to uplist to a major exchange in 2021, highlighting its commitment to enhance shareholder value. The company has submitted an application for listing, aiming to align its capital needs with growth potential in a market exceeding $3 billion in annual sales. CEO Waqaas Al-Siddiq reaffirmed the company's plans to broaden its investor base and capitalize on market opportunities as they progress towards uplisting.
Biotricity (OTCQB:BTCY) will present its flagship product, Bioflux, at the Benzinga Global Small Cap Conference on May 14, 2021. The presentation, led by CEO Waqaas Al-Siddiq, will focus on Bioflux, a wearable device for real-time cardiac monitoring and diagnosis. Scheduled for 3:35 PM ET, investors can register for access and view the presentation on YouTube. Biotricity is redefining remote healthcare with innovative monitoring solutions aimed at chronic conditions. For more information, visit biotricity.com.
Biotricity (OTCQB:BTCY) announced that its Biotres device is a finalist in Fast Company's 2021 World Changing Ideas Awards. This recognition reflects the company's commitment to innovation in healthcare technology. Dr. Waqaas Al-Siddiq, CEO, emphasized the device's potential to enhance cardiac diagnostics by providing timely patient insights for better detection and diagnosis of heart conditions. The awards program selected 400 finalists from over 4,000 entries, underscoring Biotricity’s innovative efforts in improving healthcare quality and patient compliance.
Biotricity Reports Record Revenue Growth
Biotricity (OTCQB:BTCY) announces a remarkable 133% increase in gross revenues for fiscal 2021, totaling $3.3 million. The fourth quarter alone saw a 203% year-over-year revenue boost. March 2021 set a record with over $580,000 in technology fees, projecting a revenue run rate of approximately $7 million annually. The company remains optimistic about continued growth, driven by reopening businesses post-COVID and a solid recurring revenue model.
Biotricity Inc. (OTCQB: BTCY) announced a new interview featuring CEO Dr. Waqaas Al-Siddiq, discussing the company's innovative cardiac monitoring solutions. The flagship product, Bioflux®, is a wearable device enabling real-time cardiac patient monitoring. Biotricity's growth strategy includes expanding its sales presence across 20 U.S. states, building a sales force, and launching new products. Dr. Al-Siddiq emphasizes the company’s focus on technology over clinical practices, reinforcing a recurring revenue model aimed at enhancing long-term value for investors.
Biotricity (OTCQB:BTCY) announced that CEO Waqaas Al-Siddiq will present at Maxim Group's Inaugural Emerging Growth Virtual Conference from March 17-19, 2021. Al-Siddiq will participate in a Healthcare IT panel on March 18 from 3:30-4:30 PM ET and a fireside chat on March 19 from 11:30 AM-12:00 PM ET. Investors can register for the conference and request one-on-one meetings with Biotricity management post-conference. Biotricity focuses on innovative remote health monitoring solutions for chronic care management.
Biotricity (OTCQB:BTCY) announced its unaudited financial results for Q3 fiscal 2021, reporting a record revenue of $1 million, reflecting a remarkable 162% year-over-year increase and a 34.5% sequential growth. The gross margin improved to 49.2% from 43.6% in the prior quarter. Despite a net loss of $0.11 per share, the company anticipates continued triple-digit revenue growth for the remainder of 2021, supported by resources from convertible debt financing and a planned geographic expansion. Full results will be available on EDGAR on February 16, 2021.
FAQ
What is the current stock price of BIOTRICITY (BTCY)?
What is the market cap of BIOTRICITY (BTCY)?
What is Biotricity, Inc.?
What are some of Biotricity's products?
What is the vision of Biotricity, Inc.?
How does Biotricity contribute to the healthcare industry?
